Stock Analysis
Thermo Fisher Scientific Inc. (TMO) Stock Analysis
Thermo Fisher Scientific Inc. (TMO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Thermo Fisher Scientific Inc. (TMO) currently has an AIQ Score of 55/100, indicating a neutral setup. Momentum is the strongest factor at 82/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
TMO at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $697.00 |
| AIQ Score | 55/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $249.14B |
| P/E Ratio (TTM) | 35.48 |
| Forward P/E | — |
| EPS (quarter ended 2026-09-26) | $4.65 |
| Revenue (quarter ended 2026-09-26) | $12.14B |
| Dividend Yield (TTM) | 0.27% |
| Beta | 0.88 |
| Volume | 2.09M |
| 52-week range | $435.27-$711.85 |
| RSI 14 | 70.34 |
| 50-Day SMA | $653.26 |
| 200-Day SMA | $550.99 |
| Analyst Price Target | $669.73 |
| Next Earnings | Feb 4, 2027 |
TMOThermo Fisher Scientific Inc.
Healthcare / Medical - Diagnostics & Research
Low Priority
In Line With Peers
Latest quote
- Momentum82
- Value34
- Quality51
- Risk resilience63
- Sentiment—
TMO Stock Analysis Summary
Thermo Fisher Scientific Inc. (TMO) currently has an AIQ Score of 55/100, indicating a neutral setup. Momentum is the strongest factor at 82/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, TMO has AIQ Score of 55/100 with Momentum base of 82/100 and fading Value at 34/100. Wait for component alignment before adding exposure.
Momentum (82/100) leads while Value (34/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.72% stock move · TMO classified in Medical - Diagnostics & Research.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is TMO Bullish or Bearish Right Now?
TMO currently has a neutral overall setup. Momentum is the strongest factor at 82/100, while Value is weakest at 34/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 82/100.
- - Risk Resilience is supportive at 63/100.
- - Price is +6.70% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (38 vs 6).
- - Value is the current constraint at 34/100.
- - Analyst target implies -3.91% downside from the latest quote.
Current Consensus
TMO's Technical Analysis Consensus is currently Strong Buy, with 38 buy, 1 neutral, and 6 sell votes. TMO's 14-day RSI is 70.34, which places the stock in an overbought momentum range. TMO's beta is 0.88, indicating market sensitivity broadly in line with the market.
What Changed in TMO?
The largest recent change in TMO is Momentum moving up by 15.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the TMO Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
TMO Decision Framework
Public evidence layers, setup checks, and risk context for Thermo Fisher Scientific Inc..
Thermo Fisher Scientific Inc. (TMO) Stock Analysis
Thermo Fisher Scientific Inc. has an AIQ Score of 55/100 in a Neutral regime. Momentum is strongest at 82/100. Beta is 0.88, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | TMO is in a Neutral AIQ regime with score 55/100. |
| Signal Conflict | The primary conflict is that momentum leads at 82/100 while value lags at 34/100. |
| Factor Evidence | Momentum 82/100 · Value 34/100 · Quality 51/100 · Risk 63/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 82/100.
Momentum is 82/100 and RSI (14) is 70.3.
TMO is in a Neutral regime at 55/100.
Risk factor is 63/100 with beta 0.88 and annual volatility 29.26%.
Current conflict: momentum leads at 82/100 while value lags at 34/100.
TMO Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
TMO Fundamentals
TMO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
TMO Technical Analysis
TMO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
TMO Stock Catalysts
Track TMO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
TMO Dividend Analysis
TMO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
TMO Financial Data
TMO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
TMO Risk Analysis
TMO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
TMO Stock News
TMO stock news, market tone, recent headlines, and catalyst context.
TMO vs Life Sciences / Tools / CRO Peers
Current peer cohort: TMO · TXG · ZTS · A · CDNA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| TMO Current stock | 55/100 | 34/100 | 82/100 | 63/100 | 0.83 | 29.26% | Current |
| TXG 10x Genomics | 50/100 | 34/100 | 64/100 | 38/100 | 2.8 | 74.72% | TMO vs TXG |
| ZTS Zoetis | 65/100 | 62/100 | 66/100 | 62/100 | -1.46 | 38.54% | TMO vs ZTS |
| A Agilent Technologies | 60/100 | 37/100 | 76/100 | 66/100 | 0.76 | 32.53% | TMO vs A |
| CDNA CareDx | 61/100 | 27/100 | 78/100 | 39/100 | 2.51 | 72.88% | TMO vs CDNA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 30, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 26, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching TMO
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for TMO
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
TMO Stock FAQ
What is TMO stock price today?
Thermo Fisher Scientific Inc.'s current stock price is $697.00. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is TMO bullish or bearish right now?
TMO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is TMO's market cap?
TMO's market cap is $249.14B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is TMO's current P/E ratio?
TMO's current P/E ratio is 35.48 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is TMO's RSI?
TMO's 14-day RSI is 70.34 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is TMO above its 50-day and 200-day moving averages?
TMO is 6.70% from its 50-day SMA and 26.50% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is TMO's next earnings date?
TMO's next earnings date is currently listed as Feb 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does TMO pay a dividend?
TMO's dividend yield is 0.27% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.